2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
1265
Specimen Handling
926
Magnetic Resonance Spectroscopy
830
Carboplatin
823
Cyclophosphamide
800
Cisplatin
723
Nivolumab
669
Paclitaxel
627
Radiotherapy
611
Gemcitabine
573
Biopsy
557
Bevacizumab
478
Dexamethasone
438
fludarabine
407
Docetaxel
380
venetoclax
368
Oxaliplatin
364
Capecitabine
358
Fluorouracil
355
atezolizumab
350
durvalumab
332
Rituximab
330
Drug Therapy
326
Doxorubicin
316
Radiosurgery
315
Standard of Care
309
Blood Specimen Collection
308
Pemetrexed
305
Ipilimumab
299
Radiation
286
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
bexmarilimab
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled
NCT07460986
2026-03-10
BEXAR
MedSIR
Phase 1/2
Not yet recruiting
278 enrolled